Home > Haematology > ASH 2021 > Multiple Myeloma > ASH 2021 Highlights Podcast

ASH 2021 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
ASH 2021


In this episode (19.51 min), Medicom’s correspondent covers 6 presentations from the 63rd American Society of Hematology (ASH 2021) which was held as a hybrid event based in Atlanta, Georgia USA, 11-14 December 2021.

  1. Fitusiran meets primary endpoint in ATLAS-A/B trial
    Fitusiran prophylactic therapy reduced the annual bleeding rate (ABR) in patients with severe haemophilia A or B without inhibitors. An increase in quality of life was associated with fitusiran therapy. Moreover, fitusiran offers a reduced treatment burden compared with factor replacement therapy. No new safety issues of this agent emerged.
  2. POLARIX: Novel regimen superior to R-CHOP in diffuse large B-cell lymphoma
    Polatuzumab vedotin added to rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) outperformed the standard-of-care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as initial treatment in patients with diffuse large B-cell lymphoma (DLBCL). The safety profiles of the 2 regimens were comparable. These results suggest that Pola-R-CHP may be the preferred first-line therapy in this population.
  3. rFVIIIFc establishes rapid tolerization in haemophilia A with inhibitors
    Recombinant factor VIII Fc protein (rFVIIIFc) therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent immune tolerance induction (ITI) therapy for the first time. In addition, the agent displayed a swift time to tolerization and no relapses occurred in this population. These results add to optimisation of ITI therapy, with the purpose of eradicating inhibitors in these patients [1].
  4. Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
    A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations displayed treatment resistance. The safety profile of this combination did not show unexpected issues.
  5. TRIMM-2: favourable results of talquetamab plus daratumumab for multiple myeloma
    Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM). Furthermore, the combination regimen was tolerable and did not show overlapping toxicity. This novel dual therapy is therefore a promising option for the treatment of patients with MM.
  6. Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
    The combination therapy of eprenetapopt plus azacytidine showed favourable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukaemia (AML). Patients with biallelic TP53 mutations or complex karyotype at baseline, a high-risk subpopulation, had higher complete response rates than patients who do not display these features.

Enjoy listening!

Copyright ©2021 Medicom Medical Publisher

Posted on